Last edition
News about "Kenalog"
Piramal Pharma Acquires Global Rights to Kenalog Brand in Up to USD 100 Million Deal
Piramal Pharma has agreed to acquire the global rights to the Kenalog brand and its associated injectable corticosteroid products from Bristol-Myers Squibb in a deal valued at up to USD 100 million. The acquisition will be executed through Piramal’s wholly owned subsidiary, Piramal Critical Care B.V.
Kenalog | 02/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members